Enamine and Endogena's Persistent Collaboration Paves the Way for Regenerative Medicine Advancements

by Andrii Buvailo, PhD          Biopharma insight / News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1220    Comments 0
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

In a world where innovation and collaboration play a critical role in the development of cutting-edge therapies, Enamine Ltd. and Endogena Therapeutics AG have forged a strong partnership to drive advancements in endogenous regenerative medicine. The two companies have been working together since 2019, overcoming the challenges presented by the war in Ukraine and showing the resilience of their research relationship.

Enamine, a company established in Kyiv in 1991, has grown to become a leading global designer and the largest producer of building blocks, fragments, and screening libraries. Their expertise in advanced organic synthesis, library synthesis, and medicinal chemistry has provided Endogena with invaluable support in their small molecule drug discovery programs, aiding in hit finding, hit-to-lead, and lead optimization.

Endogena Therapeutics, a clinical-stage biotech company, focuses on developing first-in-class endogenous regenerative medicines for repairing and regenerating tissues and organs. Their approach has the potential to revolutionize the treatment of degenerative conditions related to aging and genetic disorders, targeting diseases such as retinitis pigmentosa and geographic atrophy secondary to AMD.

Despite the ongoing conflict in Ukraine, Enamine has managed to maintain its high-quality services backed by an unparalleled collection of diverse building blocks. This resilience has not gone unnoticed by Endogena, whose Vice President of Medicinal Chemistry, Sven Weiler, commended the interaction and flexibility of working with Enamine. He emphasized the value of having access to their vast compound collection and praised the Enamine team for their responsiveness and ability to keep pace even during challenging times.

On the other hand, Michael Bossert, Head of Strategic Alliances at Enamine, expressed gratitude for their long-lasting partnership with Endogena, which they have served with extensive medicinal chemistry and SAR efforts. Despite the challenges, the two companies continue to push the boundaries of drug discovery, paving the way for novel and highly efficacious treatments for patients in need.

In a world that's constantly changing, the unwavering collaboration between Enamine and Endogena showcases the power of innovation, resilience, and trust between organizations. Their joint efforts serve as a beacon of hope for the development of groundbreaking therapies that can change lives for the better.

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *